PMID- 37740882
OWN - NLM
STAT- MEDLINE
DCOM- 20231124
LR  - 20231124
IS  - 1865-7265 (Electronic)
IS  - 1865-7265 (Linking)
VI  - 16
IP  - 6
DP  - 2023 Dec
TI  - Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib 
      alone for advanced hepatocellular carcinoma: a systematic review and 
      meta-analysis.
PG  - 793-802
LID - 10.1007/s12328-023-01860-4 [doi]
AB  - The clinical benefits and safety of hepatic arterial infusion chemotherapy (HAIC) 
      combined with sorafenib versus sorafenib alone for advanced HCC are inconsistent 
      in clinical studies. This meta-analysis aims to evaluate the effectiveness and 
      safety of HAIC combined with sorafenib versus sorafenib alone for advanced 
      hepatocellular carcinoma (HCC). We searched the database up to March 1, 2023, for 
      studies evaluating the effectiveness and safety of HAIC combined with sorafenib 
      versus sorafenib alone for advanced HCC. This study was registered in PROSPERO 
      (CRD42022323712). Outcomes included overall survival (OS), progression-free 
      survival (PFS), objective response rate (ORR), diseases control rate (DCR), and 
      adverse effects (AEs). The hazard ratio (HR) and odd ratio (OR) with 95% 
      confidence intervals (CI) were used to measure the pooled effect. Six studies 
      with 318 patients in the combination group and 338 patients in the control group 
      were included. Meta-analysis showed that HAIC combined with sorafenib 
      significantly improves OS compared with sorafenib alone (HR = 9.70, 95% CI 
      4.52-20.82] and HAIC combined with sorafenib significantly improves PFS compared 
      with sorafenib alone (HR = 9.48, 95% CI 4.47-20.13). Besides, HAIC combined with 
      sorafenib did not show significantly advantage of DCR rate (OR = 1.85, 95% CI 
      0.93-3.69), but associated with higher rates of ORR compared with sorafenib alone 
      (OR = 9.85, 95% CI 3.05-31.85). HAIC combined with sorafenib can achieve a better 
      effect and survival benefits than sorafenib alone in patients with advanced HCC, 
      but the limitation should be treated with cautions.
CI  - (c) 2023. Japanese Society of Gastroenterology.
FAU - Kong, Shunyu
AU  - Kong S
AUID- ORCID: 0000-0001-8644-2720
AD  - Department of Interventional Radiology, Tangdu Hospital, The Air Force Medical 
      University, Xi'an, China.
FAU - Yu, Haidong
AU  - Yu H
AUID- ORCID: 0000-0002-0984-8249
AD  - Department of Interventional Therapy, Qinghai University Affiliated Hospital, 
      Xining, China.
FAU - Wang, Haojie
AU  - Wang H
AD  - Department of Interventional Therapy, Qinghai University Affiliated Hospital, 
      Xining, China.
FAU - Song, Jiaojiao
AU  - Song J
AD  - Department of Ultrasound, Xi'an People's Hospital, Xi'an, China.
FAU - Yan, Jingxin
AU  - Yan J
AUID- ORCID: 0000-0002-2734-6146
AD  - Department of Interventional Therapy, Qinghai University Affiliated Hospital, 
      Xining, China. jingxinyan1997@126.com.
AD  - Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai 
      University, Xining, China. jingxinyan1997@126.com.
AD  - West China Hospital, , Sichuan University, Chengdu, China. 
      jingxinyan1997@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230923
PL  - Japan
TA  - Clin J Gastroenterol
JT  - Clinical journal of gastroenterology
JID - 101477246
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy/pathology
MH  - Sorafenib/adverse effects
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - Treatment Outcome
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Infusions, Intra-Arterial/adverse effects
OTO - NOTNLM
OT  - Hepatic arterial infusion chemotherapy combined
OT  - Hepatocellular carcinoma
OT  - Meta-analysis
OT  - Sorafenib
OT  - Systematic review
EDAT- 2023/09/23 20:42
MHDA- 2023/11/24 06:42
CRDT- 2023/09/23 11:10
PHST- 2023/06/29 00:00 [received]
PHST- 2023/09/06 00:00 [accepted]
PHST- 2023/11/24 06:42 [medline]
PHST- 2023/09/23 20:42 [pubmed]
PHST- 2023/09/23 11:10 [entrez]
AID - 10.1007/s12328-023-01860-4 [pii]
AID - 10.1007/s12328-023-01860-4 [doi]
PST - ppublish
SO  - Clin J Gastroenterol. 2023 Dec;16(6):793-802. doi: 10.1007/s12328-023-01860-4. 
      Epub 2023 Sep 23.